LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the
"Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to seek the role
of lead plaintiff in a federal securities class action that has been
filed against the Company.

If you invested in Lexicon stock or options between March 11, 2016
and January 17, 2019 and would like to discuss your legal rights, click
here: www.faruqilaw.com/LXRX.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292
or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the U.S. District Court for the Southern
District of Texas on behalf of all those who purchased Lexicon
securities between March 11, 2016 and January 17, 2019 (the "Class
Period"). The case, Manopla v. Lexicon Pharmaceuticals, Inc. et
al., No. 19-cv-00301 was filed on January 28, 2019, and has been
assigned to Judge Ewing Werlein, Jr.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by making false and/or misleading statements
and/or failed to disclose that: (1) the data from Lexicon’s Phase 3
clinical trials assessing the safety and efficacy of Sotagliflozin in
treating type 1 diabetes were not as positive as Lexicon represented;
(2) the health risks posed by Sotagliflozin were severe enough to
threaten its FDA approval prospects; and (3) as a result, Lexicon’s
public statements were materially false and misleading at all relevant
times.

On January 17, 2019, Lexicon announced that the Endocrinologic and
Metabolic Drugs Advisory Committee of the FDA (the "Advisory Committee")
had "voted eight to eight on the question of whether the overall
benefits of [Lexicon’s product] Zynquista (sotagliflozin) outweighed the
risks to support approval."

On this news, Lexicon's share price fell from $7.70 per share on January
17, 2019 to a closing price of $5.96 on January 18, 2019: a $1.74 or a
22.60% drop.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Lexicon's conduct to contact the firm, including whistleblowers, former
employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190319005881/en/